Click here to get full coverage on QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill

QUINCE THERAPEUTICS INC (QNCX) Stock Chart  ChartMill

QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill

Click here to get full coverage on Quince Therapeutics (QNCX) director receives 2,700 stock options grant - Stock Titan

Quince Therapeutics (QNCX) director receives 2,700 stock options grant  Stock Titan

Quince Therapeutics (QNCX) director receives 2,700 stock options grant - Stock Titan

Click here to get full coverage on Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Yahoo Finance

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy  Yahoo Finance

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Yahoo Finance

Click here to get full coverage on Number of shareholders of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView

Number of shareholders of Quince Therapeutics, Inc. – NASDAQ:QNCX  TradingView

Number of shareholders of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView

Click here to get full coverage on Quince Therapeutics Inc (QNCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Quince Therapeutics Inc (QNCX) Dividends & Stock Splits: Historical Payouts and Event Timeline  TradingKey

Quince Therapeutics Inc (QNCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Click here to get full coverage on Quince Therapeutics (QNCX) director granted stock options for 2,700 shares - Stock Titan

Quince Therapeutics (QNCX) director granted stock options for 2,700 shares  Stock Titan

Quince Therapeutics (QNCX) director granted stock options for 2,700 shares - Stock Titan

Click here to get full coverage on QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings - Quiver Quantitative

QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings  Quiver Quantitative

QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings - Quiver Quantitative

Click here to get full coverage on Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings  TradingKey

Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Click here to get full coverage on Quince Therapeutics (QNCX) joint filing reports ~7.2% ownership by Millennium group - Stock Titan

Quince Therapeutics (QNCX) joint filing reports ~7.2% ownership by Millennium group  Stock Titan

Quince Therapeutics (QNCX) joint filing reports ~7.2% ownership by Millennium group - Stock Titan

Click here to get full coverage on Quince Therapeutics Inc (QNCX) Institutional Confidence - TradingKey

Quince Therapeutics Inc (QNCX) Institutional Confidence  TradingKey

Quince Therapeutics Inc (QNCX) Institutional Confidence - TradingKey

Click here to get full coverage on Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range - Stock Titan

Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range  Stock Titan

Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range - Stock Titan

Click here to get full coverage on Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution  TradingKey

Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Click here to get full coverage on Quince Therapeutics (QNCX) officer awarded multi-million share option grants - Stock Titan

Quince Therapeutics (QNCX) officer awarded multi-million share option grants  Stock Titan

Quince Therapeutics (QNCX) officer awarded multi-million share option grants - Stock Titan

Click here to get full coverage on Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis  TradingKey

Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Click here to get full coverage on Quince Therapeutics (NASDAQ: QNCX) files Form 3 for officer Brigette Roberts - Stock Titan

Quince Therapeutics (NASDAQ: QNCX) files Form 3 for officer Brigette Roberts  Stock Titan

Quince Therapeutics (NASDAQ: QNCX) files Form 3 for officer Brigette Roberts - Stock Titan

Click here to get full coverage on Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis  TradingKey

Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Click here to get full coverage on [8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan

[8-K] Quince Therapeutics, Inc. Reports Material Event  Stock Titan

[8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan

Click here to get full coverage on Quince Therapeutics (QNCX) hit with dual Nasdaq listing deficiency notices - Stock Titan

Quince Therapeutics (QNCX) hit with dual Nasdaq listing deficiency notices  Stock Titan

Quince Therapeutics (QNCX) hit with dual Nasdaq listing deficiency notices - Stock Titan

Click here to get full coverage on Quince Therapeutics (QNCX) delays 2025 10-K after failed Phase 3; seeks 15-day extension - Stock Titan

Quince Therapeutics (QNCX) delays 2025 10-K after failed Phase 3; seeks 15-day extension  Stock Titan

Quince Therapeutics (QNCX) delays 2025 10-K after failed Phase 3; seeks 15-day extension - Stock Titan

Click here to get full coverage on Quince Therapeutics (QNCX) restores bid compliance but still below $50M MVLS - Stock Titan

Quince Therapeutics (QNCX) restores bid compliance but still below $50M MVLS  Stock Titan

Quince Therapeutics (QNCX) restores bid compliance but still below $50M MVLS - Stock Titan

Click here to get full coverage on Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages  TradingKey

Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Click here to get full coverage on Lead drug failure leaves Quince (QNCX) banking on reverse merger - Stock Titan

Lead drug failure leaves Quince (QNCX) banking on reverse merger  Stock Titan

Lead drug failure leaves Quince (QNCX) banking on reverse merger - Stock Titan

Click here to get full coverage on Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits

Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout?  Stocktwits

Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits

Click here to get full coverage on Why Did QNCX Stock Plummet Over 90% Today? - Stocktwits

Why Did QNCX Stock Plummet Over 90% Today?  Stocktwits

Why Did QNCX Stock Plummet Over 90% Today? - Stocktwits

Click here to get full coverage on QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger - Stocktwits

QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger  Stocktwits

QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger - Stocktwits

Click here to get full coverage on $QNCX stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

$QNCX stock is up 11% today. Here's what we see in our data.  Quiver Quantitative

$QNCX stock is up 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Quince Therapeutics Inc (QNCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Quince Therapeutics Inc (QNCX) Risk Assessment: Volatility, Financial Risk & Investment Risk  TradingKey

Quince Therapeutics Inc (QNCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Click here to get full coverage on Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Sahm

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks  Sahm

Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks - Sahm

Click here to get full coverage on QNCX: Lead asset failed in Phase 3, triggering strategic review and raising going concern risks - TradingView

QNCX: Lead asset failed in Phase 3, triggering strategic review and raising going concern risks  TradingView

QNCX: Lead asset failed in Phase 3, triggering strategic review and raising going concern risks - TradingView

Click here to get full coverage on Quince Therapeutics (QNCX) retires about $16.4M EIB loan with $5.5M payment - Stock Titan

Quince Therapeutics (QNCX) retires about $16.4M EIB loan with $5.5M payment  Stock Titan

Quince Therapeutics (QNCX) retires about $16.4M EIB loan with $5.5M payment - Stock Titan

Click here to get full coverage on Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly? - simplywall.st

Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly?  simplywall.st

Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly? - simplywall.st

Click here to get full coverage on QNCX Stock Slides As Traders React To Volatile Price Action - StocksToTrade

QNCX Stock Slides As Traders React To Volatile Price Action  StocksToTrade

QNCX Stock Slides As Traders React To Volatile Price Action - StocksToTrade

Click here to get full coverage on QNCX: Acquisition and financing secure LAM-001’s development for rare pulmonary diseases through 2028 - TradingView

QNCX: Acquisition and financing secure LAM-001’s development for rare pulmonary diseases through 2028  TradingView

QNCX: Acquisition and financing secure LAM-001’s development for rare pulmonary diseases through 2028 - TradingView

Click here to get full coverage on Steroid-based A-T treatment shows stable growth in children study - Stock Titan

Steroid-based A-T treatment shows stable growth in children study  Stock Titan

Steroid-based A-T treatment shows stable growth in children study - Stock Titan

Click here to get full coverage on Wondering what's happening in today's after-hours session? - ChartMill

Wondering what's happening in today's after-hours session?  ChartMill

Wondering what's happening in today's after-hours session? - ChartMill

Click here to get full coverage on Quince Therapeutics (QNCX) acquires Orphai and secures up to $187M PIPE - Stock Titan

Quince Therapeutics (QNCX) acquires Orphai and secures up to $187M PIPE  Stock Titan

Quince Therapeutics (QNCX) acquires Orphai and secures up to $187M PIPE - Stock Titan

Click here to get full coverage on QNCX Should I Buy - Intellectia AI

QNCX Should I Buy - Intellectia AI

Click here to get full coverage on Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - Yahoo Finance

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives  Yahoo Finance

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives - Yahoo Finance

Click here to get full coverage on $QNCX stock is up 117% today. Here's what we see in our data. - Quiver Quantitative

$QNCX stock is up 117% today. Here's what we see in our data.  Quiver Quantitative

$QNCX stock is up 117% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Trial setback and cash strain shape Quince (NASDAQ: QNCX) Q1 update - Stock Titan

Trial setback and cash strain shape Quince (NASDAQ: QNCX) Q1 update  Stock Titan

Trial setback and cash strain shape Quince (NASDAQ: QNCX) Q1 update - Stock Titan

Click here to get full coverage on Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics Inc - M&A Call - Slideshow (NASDAQ:QNCX) 2026-05-18 - Seeking Alpha

Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics Inc - M&A Call - Slideshow (NASDAQ:QNCX) 2026-05-18  Seeking Alpha

Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics Inc - M&A Call - Slideshow (NASDAQ:QNCX) 2026-05-18 - Seeking Alpha

Click here to get full coverage on Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - GlobeNewswire

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline  GlobeNewswire

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - GlobeNewswire

Click here to get full coverage on Nantahala Capital (QNCX) reports 4.53M shares, 7.52% stake disclosed - Stock Titan

Nantahala Capital (QNCX) reports 4.53M shares, 7.52% stake disclosed  Stock Titan

Nantahala Capital (QNCX) reports 4.53M shares, 7.52% stake disclosed - Stock Titan

Click here to get full coverage on Insider Sale: Director at $QNCX Sells 50,000 Shares - Quiver Quantitative

Insider Sale: Director at $QNCX Sells 50,000 Shares  Quiver Quantitative

Insider Sale: Director at $QNCX Sells 50,000 Shares - Quiver Quantitative

Click here to get full coverage on Quince Therapeutics Announces 1-for-10 Reverse Stock Split - The Globe and Mail

Quince Therapeutics Announces 1-for-10 Reverse Stock Split  The Globe and Mail

Quince Therapeutics Announces 1-for-10 Reverse Stock Split - The Globe and Mail

Click here to get full coverage on Which stocks are most active on Tuesday? - ChartMill

Which stocks are most active on Tuesday?  ChartMill

Which stocks are most active on Tuesday? - ChartMill

Click here to get full coverage on Curious about the most active stocks on Wednesday? - ChartMill

Curious about the most active stocks on Wednesday?  ChartMill

Curious about the most active stocks on Wednesday? - ChartMill

Click here to get full coverage on Quince Therapeutics stock plummets after revealing strategic alternatives - Investing.com

Quince Therapeutics stock plummets after revealing strategic alternatives  Investing.com

Quince Therapeutics stock plummets after revealing strategic alternatives - Investing.com

Click here to get full coverage on Quince Therapeutics to implement 1-for-10 reverse stock split effective Friday - Investing.com

Quince Therapeutics to implement 1-for-10 reverse stock split effective Friday  Investing.com

Quince Therapeutics to implement 1-for-10 reverse stock split effective Friday - Investing.com

Click here to get full coverage on LAM-001 trial shows gains in PH-ILD patients for Quince Therapeutics (QNCX) - Stock Titan

LAM-001 trial shows gains in PH-ILD patients for Quince Therapeutics (QNCX)  Stock Titan

LAM-001 trial shows gains in PH-ILD patients for Quince Therapeutics (QNCX) - Stock Titan

Click here to get full coverage on QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings - Moomoo

QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings  Moomoo

QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings - Moomoo

Click here to get full coverage on QNCX Stock Plummets 88% After Ceasing eDSP Development - GuruFocus

QNCX Stock Plummets 88% After Ceasing eDSP Development  GuruFocus

QNCX Stock Plummets 88% After Ceasing eDSP Development - GuruFocus

Click here to get full coverage on Quince Therapeutics Faces Nasdaq Listing Compliance Deficiencies - The Globe and Mail

Quince Therapeutics Faces Nasdaq Listing Compliance Deficiencies  The Globe and Mail

Quince Therapeutics Faces Nasdaq Listing Compliance Deficiencies - The Globe and Mail

Click here to get full coverage on Quince Therapeutics (QNCX) Expands Pipeline with Acquisition of - GuruFocus

Quince Therapeutics (QNCX) Expands Pipeline with Acquisition of  GuruFocus

Quince Therapeutics (QNCX) Expands Pipeline with Acquisition of - GuruFocus

Click here to get full coverage on Quince Therapeutics (QNCX) Downgraded by Citizens to Market Perf - GuruFocus

Quince Therapeutics (QNCX) Downgraded by Citizens to Market Perf  GuruFocus

Quince Therapeutics (QNCX) Downgraded by Citizens to Market Perf - GuruFocus

Click here to get full coverage on Quince Therapeutics Pursues Reverse Merger Amid Restructuring Effort - The Globe and Mail

Quince Therapeutics Pursues Reverse Merger Amid Restructuring Effort  The Globe and Mail

Quince Therapeutics Pursues Reverse Merger Amid Restructuring Effort - The Globe and Mail

Click here to get full coverage on Quince Therapeutics (QNCX) Shares Drop as Phase 3 Trial Misses K - GuruFocus

Quince Therapeutics (QNCX) Shares Drop as Phase 3 Trial Misses K  GuruFocus

Quince Therapeutics (QNCX) Shares Drop as Phase 3 Trial Misses K - GuruFocus

Click here to get full coverage on Quince Therapeutics stock soars after engaging LifeSci Capital as advisor - Investing.com

Quince Therapeutics stock soars after engaging LifeSci Capital as advisor  Investing.com

Quince Therapeutics stock soars after engaging LifeSci Capital as advisor - Investing.com

Click here to get full coverage on Quince Therapeutics (QNCX) Faces Setback with Phase 3 Trial Resu - GuruFocus

Quince Therapeutics (QNCX) Faces Setback with Phase 3 Trial Resu  GuruFocus

Quince Therapeutics (QNCX) Faces Setback with Phase 3 Trial Resu - GuruFocus

Click here to get full coverage on Quince Therapeutics stock tumbles after failed Phase 3 trial results - Investing.com

Quince Therapeutics stock tumbles after failed Phase 3 trial results  Investing.com

Quince Therapeutics stock tumbles after failed Phase 3 trial results - Investing.com

Click here to get full coverage on QNCX Stock Slides As Traders Weigh Cash Runway And Volatility - timothysykes.com

QNCX Stock Slides As Traders Weigh Cash Runway And Volatility  timothysykes.com

QNCX Stock Slides As Traders Weigh Cash Runway And Volatility - timothysykes.com

Click here to get full coverage on UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - GlobeNewswire

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD  GlobeNewswire

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - GlobeNewswire

Click here to get full coverage on Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60 - MSN

Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60  MSN

Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60 - MSN

Click here to get full coverage on Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital - Investing.com Nigeria

Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital  Investing.com Nigeria

Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital - Investing.com Nigeria

Click here to get full coverage on Quince regains Nasdaq compliance after reporting $15.7M stockholders' equity - TradingView

Quince regains Nasdaq compliance after reporting $15.7M stockholders' equity  TradingView

Quince regains Nasdaq compliance after reporting $15.7M stockholders' equity - TradingView

Click here to get full coverage on Quince Therapeutics appoints June Bray to board of directors - Investing.com

Quince Therapeutics appoints June Bray to board of directors  Investing.com

Quince Therapeutics appoints June Bray to board of directors - Investing.com

Click here to get full coverage on Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure - Clinical Trials Arena

Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure  Clinical Trials Arena

Quince Therapeutics’ stock crashes on Phase III ataxia-telangiectasia failure - Clinical Trials Arena

Click here to get full coverage on Quince Therapeutics (QNCX) Approves Reverse Stock Split—SEC 8-K Filing Details (June 11, 2026) - Minichart

Quince Therapeutics (QNCX) Approves Reverse Stock Split—SEC 8-K Filing Details (June 11, 2026)  Minichart

QNCX

Price Chart

Key Statistics

Technicals

About QNCX

Latest News

QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill

Quince Therapeutics (QNCX) director receives 2,700 stock options grant - Stock Titan

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers